AN ABSTRACT OF THE LIMT HDV STUDY

Objectives

- Evaluate safety, tolerability and efficacy
- Evaluate the proportion of patients with undetectable HDV RNA:
  - 12 weeks after the end of treatment
  - 24 weeks after the end of treatment

Study Sites

- Auckland, New Zealand (N=4)
- Karachi, Pakistan (N=15)
- Barcelona, Spain (N=11)
- Tel Aviv, Israel (N=5)

Limit of quantification = 14 IU/mL

All Patients at Time of Analysis (N=33)

No responders / Responder by Week 24

Responders: 6 of 10 (60%) Patients at Week 24

Lambda Demonstrates Rapid Decline in HDV RNA

Lambda Safety at Time of Analysis

- 95% CI
- SAEs 5 (15%)
- ALT increase (>5x ULN) 18 (55%)
- Hyperbilirubinemia (>2.5x ULN) 3 (9%)b
- Influenza-like Illnessb 4 (12.1%) 4
- Myalgiaa,b 11 (33.3%) 8 3
- Pyrexiaa,b 13 (39.4%) 11 2
- Pruritus 1 (3%) 1
- Fatigue 6 (18.2%) 6
- Headache 1 (3%) 1
- Alopecia 1 (3%) 1

References

1. Wedemeyer et al, 2014 AASLD
2. Chan et al, J Hepatology, 2016